Triple-helical DNA can be formed by oligonucleotides that bind as third strands of DNA in a sequencespecific manner in the major groove in homopurine/homopyrimidine stretches in duplex DNA. Such triple helix-forming oligonucleotides have been used to inhibit gene expression by blocking transcription factor access to promoter sites in transient expression assays. In an alternative approach to genetic manipulation using triplex DNA, we show that triplex-forming oligonucleotides can be used to produce site-specific, targeted mutations in a viral genome in order to achieve a permanent, heritable effect on gene function and expression. We use a triplex-forming oligonucleotide linked to a psoralen derivative at its 5' end to achieve targeted mutagenesis in a simian virus 40 (SV40) vector genome. Site-specific triplex formation delivers the psoralen to the targeted site in the SV40 DNA. Photoactivation of the psoralen yields adducts and thereby mutations at that site. Mutations were produced in the target gene in over 6% of the viral genomes. DNA sequence analysis of the mutations in the target gene showed that all were in the targeted region, and 55% were found to be the same T:A-to-A:T transversion precisely at the targeted base pair. In control experiments, no mutagenesis above the background frequency in the assay was produced by a non-triplex-forming, psoralen-linked oligonucleotide unless a vast excess of this oligonucleotide was used, demonstrating the specificity of the targeted mutagenesis. This frequency of targeted mutagenesis of SV40 in monkey cells represents a 30-fold increase relative to similar experiments using lambda phage in bacteria, suggesting that fixation of the triplex-directed lesion into a mutation occurs more efficiently in mammalian cells. If the ability to reproducibly and predictably target mutations to sites in viral DNA in vitro by using modified oligonucleotides can be extended to DNA in vivo, this approach may prove useful as a technique for gene therapy, as a strategy for antiviral therapeutics, and as a tool for genetic engineering.
Mutations play a role in many human diseases, and it would be of benefit if disease-related mutations could be corrected or if deleterious genes could be inactivated in the cells of affected patients. One approach to this has been the replacement of a defective gene by site-directed, homologous recombination, using a vector containing the wild-type gene (5) . As an alternative approach, we set out to examine whether it would be possible to target mutations to a specific base pair in a selected gene in order to correct, modify, or inactivate that gene. Along with chromosomal genes, viral genes might be potential targets for such site-directed mutagenesis, as the ability to introduce strategically placed mutations into viral genomes infecting mammalian cells may prove useful as an approach to antiviral therapeutics. To this end, we report here experiments to study targeted mutagenesis of specific base pairs in simian virus 40 (SV40) DNA grown in monkey COS-7 cells.
To achieve targeted mutagenesis of SV40 DNA, we chose to take advantage of the ability of oligonucleotides to bind to double-stranded DNA and form triple helices in a sequencespecific manner. Linkage of the triplex-forming oligonucleotides to a potentially mutagenic chemical, such as psoralen, is designed to deliver the mutagen into proximity with the chosen site in the viral DNA, producing a lesion at that site and leading to a mutation.
Triplex DNA can be formed when oligonucleotides bind as third strands of DNA in the major groove of the double helix in homopurine/homopyrimidine sequences. In one motif, a * Corresponding author.
homopyrimidine oligonucleotide binds in a direction parallel to the purine strand in the duplex (26, 31) . In the alternate purine motif, a homopurine strand binds antiparallel to the purine strand in the Watson-Crick duplex, with A binding to A:T and G binding to G:C base pairs (1) . The specificity of triplex formation arises from the base triplets formed by hydrogen bonding. Although mismatches can destabilize the triple helix, some sequence variations can occur and still allow triplex formation (2, 14, 25) .
The utility of triplex-forming oligonucleotides has been demonstrated in a variety of experiments. Oligonucleotides designed to bind to sites in gene promoters have been used to block DNA-binding proteins and to block transcription both in vitro and in vivo. For example, triple helix formation by selected oligonucleotides effectively blocked in vitro transcription from the 1-lactamase promoter (11) , and triplex formation occurring at a specific site in the mouse metallothionein I promoter was shown to block the binding of the Spl transcription factor in vitro (24) . Other work has demonstrated the binding of oligonucleotides to the human c-myc, human epidermal growth factor, mouse insulin receptor, human dihydrofolate reductase, and human interleukin-2 receptor (ox chain) gene promoters, among others (3, 7, 10, 17, 18, 27, 30) . The linkage of oligonucleotides to intercalating agents or to crosslinking agents has been utilized to enhance the stability of triplex binding via covalent bond formation in experiments designed to prevent transcription initiation or elongation in plasmid constructs (8, 31, (33) (34) (35) . Levels (28) . Psoralen-AGIO is incubated with the SV40 vector DNA to allow site-specific triplex formation. Photoactivation of the psoralen by UVA irradiation is designed to generate an adduct at the targeted base pair (bp 167), as indicated by the arrow. The oligonucleotide-plasmid complex is then transfected into monkey COS-7 cells and allowed to replicate for 48 h. Following purification of the vector DNA by the Hirt lysate procedure (22) , the DNA is used to transform E. coli SY204 lacZ125(Am) (15, 16) . Transformants are selected on ampicillin plates containing X-Gal and IPTG for detection and isolation of mutants (white colonies) in which the supF gene has been inactivated by mutation.
oligonucleotides (3, 27, 30) . Triplex-forming oligonucleotides have also been used to mediate site-specific cleavage of DNA in vitro (12, 26, 29, 33) .
Our approach has been to take advantage of the sequencedependent formation of triple-helical DNA by oligonucleotides to direct DNA damage and thereby mutations to a selected base pair in a chosen gene. We reasoned that introducing a strategically placed mutation into DNA would yield a permanent change in gene function and/or expression, as opposed to transient inhibition of transcription or translation. In our previous work, a triplex-forming oligonucleotide was used to achieve site-specific, targeted mutagenesis in a selected gene in a lambda phage genome (21) . To explore the feasibility of targeted mutagenesis of a mammalian virus and to examine the processing of the triplex-directed premutagenic lesion in mammalian cells, we performed experiments to investigate targeted mutagenesis of SV40 DNA transfected into monkey cells. In these experiments, the site-specific triplex formation is designed to deliver the mutagen, psoralen, to the targeted site in the SV40 DNA, long-wavelength UV light (UVA; 320 to 400 nm) is used to activate the psoralen to form adducts at that site, and repair and replication of the viral genomes in the monkey cells fix the adducts into mutations. These experiments demonstrate that targeted mutagenesis occurs with a higher efficiency in mammalian cells (6% of SV40 genomes incurred targeted mutations) than in bacteria (0.2% [21] Fig. 1 . The oligonucleotides used in this study were AGIO, the triplex-forming oligonucleotide (5'-AGGAAGGGGG-3'), and GAIO, the reverse-sequence control oligomer (5'-GGGGGAAGGA-3'). SV40 shuttle vector pSPI89 was obtained from Michael Seidman (28) .
Triplex binding assays. The 250-bp supF target, generated from XsupF (16) To assay for site-specific binding to the SV40 vector DNA, the binding reactions were carried out as described above except that pSP189 DNA, containing the supF gene target, was used at a concentration of 50 nM and psoralen-AGIO was added at ratios of oligomer to vector of from 1:1 to 1,000:1. Irradiation and gel conditions were as described above.
SV40 mutagenesis. The SV40 vector DNA (pSP189) at 80 nM was incubated with psoralen-AGIO or psoralen-GA10 (at ratios ranging from a 2-to 1,000-fold molar excess of oligonucleotide) and irradiated as described above. The oligonucleotide-plasmid complex was then transfected into monkey COS (9) . Colonies were grown in the presence of isothiogalactopyranoside (IPTG; 65 VLg/ml) and 5-bromo-4-chloro-3-indolyl-3-D-galactopyranoside (X-Gal; 80 pLg/ml) as described previously (15) to allow identification of mutants as white colonies among the wild-type blue ones.
In the experiment with competitor salmon sperm DNA, the binding reaction was carried out in a total volume of 20 pA containing 3.5 pg of pSP189 (50 nM), a 10:1 molar excess of psoralen-AG 10 (0.03 pLg, 500 nM), and 35 ptg of salmon sperm DNA. Irradiation, transfection, and mutant analysis were done as described above.
DNA sequencing. SV40 plasmid vector DNA was isolated for sequencing from 3-mi bacterial cultures by using a Promega Magic Miniprep kit (Promega, Madison, Wis.). DNA sequence data were obtained by direct chain termination sequencing of the plasmid DNA, using automated methods (6) .
Colony hybridization. Ampicillin-resistant colonies of SY204 carrying shuttle vector plasmids with slupF gene mutations, along with appropriate control colonies, were grown on LB-ampicillin plates and transferred onto replica nylon filters for additional growth and in situ lysis to allow colony hybridization by standard methods (32) . The DNA was fixed to the filters by UV cross-linking, and the filters were incubated in 6x SSC (1 x SSC is 0.15 M NaCl plus 0.015 M sodium citrate)-5 x Denhardt's solution, 0.5% sodium dodecyl sulfate (SDS)-5 x I(I5 cpm of 32P-labeled oligonucleotides per ml at 42°C for 18 h. The filters were washed in 3 x SSC-0.1% SDS for 30 min at 25°C and then in 3 x SSC-0. 10% SDS at 42°C for 2 h. These conditions were empirically determined to allow discrimination between binding of the wild type probe (5'-GGTTCGAATCCTTCCCCC-3') and the bp 167 mutant probe (5'-GGTTCGAAACCTTCCCCC-3'). Binding of the oligonucleotide probes was determined by autoradiography.
RESULTS
Strategy for targeted mutagenesis of SV40. In these experiments, an SV40-based shuttle vector (pSP189) was used to assay for targeted mutagenesis (28) . This vector contains both the SV40 and the pBR327 origins of replication, plus the 3-lactamase gene for ampicillin resistance, to allow episomal replication in both mammalian cells and bacteria (Fig. 1) . It also carries the slupF gene, an amber suppressor tyrosine tRNA gene of E. coli, as a marker gene for mutagenesis studies. The design of the initial experiments to target mutations to SV40 DNA is illustrated in Fig. 1 . A 10-bp region of the sutpF gene (bp 167 to 176) was identified as a site amenable to triplex formation because of the run of purines there. Since this run was G rich, the purine motif for triplex formation was selected (1), and an oligonucleotide, AGIO (5'-AGGAAGGGGG-3'), was synthesized on the basis of this motif. A psoralen derivative, 4'-hydroxymethyl-4,5',8-trimethylpsoralen, was attached to the oligonucleotide by a phosphodiester linkage at the 5' adenine via a two-carbon linker arm, with the goal of directing psoralen intercalation and adduct formation to bp 166 and 167. From our previous work targeting mutations to the sccpF gene within a lambda phage vector (21) , it was predicted that most of the mutations would be targeted to bp 167. This is the base pair with which that 5' adenine binds and forms a triad in the predicted triple helix. Note that the psoralen-AGIO oligonucleotide is oriented antiparallel to the purine-rich strand in the duplex DNA. To achieve targeted mutagenesis, the pSP189 DNA is incubated with psoralen-AGIO, treated with UVA to activate the psoralen to form a premutagenic adduct on the thymidine in bp 167, and then transfected into COS-7 cells. After a 48-h period to allow repair and replication, the viral DNA is isolated from the monkey cells by the Hirt lysate procedure (22) . The recovered viral DNA is subjected to digestion with DpnI in order to eliminate misleading data that might arise from viral DNA that was not replicated or repaired in the mammalian cells, since this enzyme will restrict DNA that has not been methylated in the mammalian pattern. The DNA is then used to transform E. coli carrying an amber mutation in the lacZ gene to allow analysis of slupF function. The frequency of suipF mutations is determined, and representative samples of sulpF mutant clones are collected for further analysis.
Site-specific formation of triplex DNA. Prior to carrying out mutagenesis studies, we first examined whether a site-specific triple helix was formed in the slupF gene by the selected oligonucleotide. In previous work, we have shown by using radioactively labeled oligonucleotides that AG10, but not the reverse-sequence oligomer (GAl0 [5'-GGGGGAAGGA-3']), binds to the slupF gene fragment in a gel mobility shift assay (21) . Here, we demonstrate the ability of psoralen-AGIO to bind not just to the slupF gene fragment but specifically to the intended site within the suIpF gene. It has been demonstrated that triple helix formation at sequences overlapping a restriction enzyme site can block digestion at that site (13, 20, 24) , and so we used a restriction enzyme protection assay in which Hinfl digestion at the one recognition site (bp 164 to 168) that overlaps the triplex target site (bp 167 to 176) was compared with digestion at the other Hinfl site in slupF (bp 129 to 133).
The design of this assay is diagrammed in Fig. 2A, In the absence of psoralen-AG10, UVA light had no effect on Hinfl digestion (lane 2). In similar experiments, no protection from Hinfl cutting was seen with use of psoralen-GAlO, the reverse-sequence oligomer linked to psoralen (data not shown). These results demonstrate site-specific formation of triplex DNA by psoralen-AG10, with covalent modification of the suipF gene fragment occurring at the targeted site following UVA irradiation of the psoralen-AGIO/slupF complex.
Similar experiments were performed to assay for site-specific binding of psoralen-AGIO to bp 167 to 176 in the suIpF gene within the SV40 vector itself (Fig. 3) . In these experiments, various ratios of oligonucleotide to vector DNA were used to examine basic parameters of the triplex binding to the viral genome. Figure 3 illustrates that Hinfl protection at the targeted site is almost complete at a 10:1 ratio of oligonucleotide to vector, as judged by the appearance in the ethidium bromide-stained agarose gel of a band at 118 bp (arrow, right) and the disappearance of the band at 83 bp (arrow, left). J/cm2, digested with Hinfl, and analyzed by agarose gel electrophoresis. Lanes: 1, undigested plasmid DNA; 2, no psoralen-AGIO prior to digestion; 3 to 7, increasing ratios of psoralen-AG1O/SV40 DNA as indicated above the lanes; 8, 100-bp size markers. Since the sequences flanking the supF gene in the SV40 DNA differ from those in the PCR fragment presented in Fig. 2 and since there are multiple Hinfl sites in SV40, the pattern of bands is more complex than in Fig. 2 . However, the arrow on the right indicates the position of the 118-bp fragment resulting from shielding of the Hinifl site at bp 164 to 168 by triplex formation, while the arrow on the left indicates the position of the 83-bp fragment that disappears when digestion at this site is blocked. Ratios of 100:1 and 1,000:1 similarly yielded nearly complete protection, whereas the lower ratios of 1:1 and 2:1 gave only partial protection. These results are consistent with those of the mutagenesis experiments described below. Since halfmaximal protection occurs between ratios of 2:1 and 10:1 (at a psoralen-AGIO concentration of between 100 and 500 nM versus 50 nM vector), it can be estimated that the equilibrium dissociation constant for psoralen-AGIO binding to slupF in these experiments is in the range of 10'-to 10 7 M. Further experiments are necessary to more precisely determine the dissociation constant.
Targeted mutagenesis of SV40 vector DNA passaged in COS cells. Experiments to induce targeted mutagenesis in SV40 vector DNA by using triplex-forming oligonucleotides were carried out as shown in Fig. 1 . Psoralen-linked oligonucleotides were incubated with SV40 vector DNA, exposed to UVA light at 1.8 J/cm2, and transfected into COS cells. After 2 days to allow repair and replication to occur, the vector DNA was rescued from the cells and used to transform bacteria to facilitate genetic analysis of the supF gene. The effect of psoralen-AGIO, which binds site specifically to the sulpF gene in the vector, in inducing slupF mutations was compared with that of psoralen-GAIO, which shows no specific binding. Various ratios of oligonucleotide to vector DNA were used to investigate parameters that might affect the specificity and the efficiency of the process of targeted mutagenesis in the monkey cells. The data obtained from these experiments are presented in Table 1 . Targeted mutations in the supF gene were produced in the SV40 genome at a frequency as high as 7.3% with use of psoralen-AGIO at a molar ratio of oligonucleotide to vector DNA of 1,000:1. At this same ratio, psoralen-GAIO produced a small amount of mutagenesis above background (0.63% versus 0.07%). At the lower ratios tested, however, the reverse oligomer yielded no significant mutagenesis above the background frequency in the assay, whereas at these lower ratios, psoralen-AGIO still generated a high frequency of mutations in supF (as high as 6.4% for the 10:1 ratio versus 0.06% for psoralen-GAIO at 10:1 and 0.07% for untreated vector DNA). This result demonstrates mutagenesis specifically targeted to the supF gene in the SV40 vector by psoralen- In other control experiments (Table 1) , UVA irradiation of the SV40 DNA, in the absence of the psoralen-linked oligonucleotides, produced no mutagenesis above background. Similarly, the treatment of the SV40 DNA with the oligomers but without UVA irradiation was not mutagenic.
Sequence analysis of targeted mutations. Twenty mutations generated in the slupF gene in the SV40 vector by psoralen-AGIO (at the 1,000:1 ratio) and UVA light were subjected to DNA sequence analysis (Fig. 4A) . Of the 20 mutations analyzed, 11 consist of the same T:A-to-A:T transversion at bp 167. This is the precise base pair to which the mutations were targeted by psoralen-AGIO, as diagrammed in Fig. 1 Improved mutational specificity may be achieved by reducing the length of the linker arm. In Fig. 4B , the published sequences of supF mutations produced by using free 8-methoxypsoralen in this same vector system in human cells (4) and in a lambda vector system in mouse cells (16, 19) are presented for comparison. Not only are these mutations more scattered, but also none were found to occur at bp 167.
In the analysis of mutagenesis in SV40 vectors, it is often difficult to determine whether identical mutations arose independently or whether they were the result of a single mutational event amplified by subsequent vector replication. To exclude the possibility that such sibling mutations were isolated in these experiments, use was made of an advantageous feature of the pSP189 system, in which over 100,000 different, randomsequence 8-bp oligonucleotides were cloned into a region of pSP189 next to the supF gene (28) . The vector DNA is prepared en masse from this library of vector clones containing the different 8-bp sequences. In this way, at the same time that the sequence of the supF gene in a mutant vector is ascertained, the 8-bp signature sequence in that particular plasmid molecule can also be identified by reading a few extra nucleotides further in the sequence. This enables comparisons between the 8-bp signature sequences in plasmids bearing the same supF mutation to determine whether they are siblings from the same mutational event or whether they are independent mutations. From this analysis, it was determined that all 20 of the mutations presented here arose independently (data not shown).
To confirm these results, a larger sample of supF mutations produced in the SV40 vector by psoralen-AGIO and UVA light was analyzed by an alternative method based on the expected high proportion of T:A-to-A:T transversions at bp 167. Instead of direct sequencing, a technique of differential oligonucleotide hybridizations was used. In this assay, undertaken in an effort to streamline mutant analysis, ampicillin-resistant bacterial colonies containing mutant suipF genes were grown on nylon filters to allow nucleic acid hybridizations. Duplicate filters were incubated with 32P-labeled, 18 -base oligonucleotides that either matched the wild-type sequence or matched the position 167 T:A-to-A:T mutant sequence. The hybridizations were carried out by standard methods (32) under conditions empirically determined to be stringent enough to allow differentiation between mutant and wild-type sequences. The results of one such analysis are shown in Fig. 5 . Of the 19 colonies assayed in this particular experiment, 9 showed hybridization specific to the mutant probe. None of the colonies showed hybridization to the wild-type probe except for the positive control in the upper right corner. Ten colonies bound neither the wild-type nor the bp 167 mutant probe, suggesting that they either have different mutations at bp 167 (not T:A to A:T) or have mutations near bp 167, within the 18-bp region covered by the probes, causing mismatches with both the wild-type and mutant oligonucleotides. A total of 42 mutants generated by psoralen-AGIO (including the 20 subjected to sequence analysis) were analyzed by this method, and 22 T  T  T  T  T  T  T  T  T  TA  C TA  5,   90  100  110  120  130  140  150  160  * 170  180   GTAAAAGCATTACCTGTGGTGGGGTTCCCGAGCGGCCAAAGGGAGCAGAC TC TAAATC TGCCG TCATCGACT TCGAAGGT TCGAATQCZCQ (16, 19) or generated in monkey Vero cells by using an SV40 shuttle vector (pZ189) almost identical to the one used in this study (4) , to show for comparison the mutations that can be produced in supF by free psoralen.
(52%) were found to carry the T:A-to-A:T mutation at bp 167. All of the rest were judged to have different mutations at or near the targeted base pair, since neither the mutant nor wild-type probe hybridized to them. The validity of this assay was supported by complete agreement with the sequencing data. These results extend the direct sequencing data and further demonstrate the targeted mutagenesis of SV40 vector DNA. Taken together, the data indicate that nearly all of the mutations produced by psoralen-AG10 are at or within a few bases of the targeted base pair, and at least 50% consist of the same T:A-to-A:T transversion at that site. These results demonstrate efficient production of specific, reproducible, and predictable mutations at a targeted base pair in SV40 DNA passaged in monkey cells.
DISCUSSION
The work presented here demonstrates the targeted mutagenesis of SV40 DNA treated in vitro with a psoralen-linked, triplex-forming oligonucleotide. This targeted mutagenesis is specific: at a ratio of oligomer to SV40 of 10:1, the triplexforming oligonucleotide, psoralen-AG10, induced mutagenesis in the supF gene at a frequency at least 100-fold above the background level of spontaneous mutations in the assay. The control, non-triplex-forming oligonucleotide, psoralen-GA10, in contrast, did not yield any mutagenesis above background at that ratio. 
